cimetidine has been researched along with Prostatic Neoplasms in 6 studies
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cimetidine has been hypothesized to exert a cancer preventive effect on the prostate due to its ability to inhibit the binding of dihydrotestosterone to androgen receptors." | 5.31 | Cimetidine use and risk of prostate and breast cancer. ( Cushing-Haugen, KL; Rossing, MA; Scholes, D; Voigt, LF, 2000) |
| "Men were followed up for subsequent prostate cancer by linkage to the Surveillance, Epidemiology and End Results cancer registry." | 1.33 | Cimetidine use and the risk for prostate cancer: results from the VITAL cohort study. ( Dublin, S; Velicer, CM; White, E, 2006) |
| "Cimetidine has been hypothesized to exert a cancer preventive effect on the prostate due to its ability to inhibit the binding of dihydrotestosterone to androgen receptors." | 1.31 | Cimetidine use and risk of prostate and breast cancer. ( Cushing-Haugen, KL; Rossing, MA; Scholes, D; Voigt, LF, 2000) |
| "All patients had bone metastases." | 1.28 | Treatment of hormone-refractory stage D carcinoma of prostate with coumarin (1,2-benzopyrone) and cimetidine: a pilot study. ( Butler, K; Hermansen, D; Marshall, ME, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Velicer, CM | 1 |
| Dublin, S | 1 |
| White, E | 1 |
| Rossing, MA | 1 |
| Scholes, D | 1 |
| Cushing-Haugen, KL | 1 |
| Voigt, LF | 1 |
| Møller, H | 1 |
| Mellemgaard, A | 1 |
| Stolinsky, DC | 1 |
| Marshall, ME | 1 |
| Butler, K | 1 |
| Hermansen, D | 1 |
| Lahat, N | 1 |
| Alexander, B | 1 |
| Levin, DR | 1 |
| Moskovitz, B | 1 |
6 other studies available for cimetidine and Prostatic Neoplasms
| Article | Year |
|---|---|
Cimetidine use and the risk for prostate cancer: results from the VITAL cohort study.
Topics: Aged; Cimetidine; Cohort Studies; Histamine H2 Antagonists; Humans; Male; Middle Aged; Proportional | 2006 |
Cimetidine use and risk of prostate and breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Case-Control Studies; Cimetidine; Female; Histamin | 2000 |
Prostate cancer incidence in cimetidine users.
Topics: Adult; Aged; Aged, 80 and over; Cimetidine; Humans; Incidence; Male; Middle Aged; Prostatic Neoplasm | 1992 |
Prostate cancer and histamine2 antagonists.
Topics: Cimetidine; Histamine Antagonists; Humans; Male; Prostatic Neoplasms | 1991 |
Treatment of hormone-refractory stage D carcinoma of prostate with coumarin (1,2-benzopyrone) and cimetidine: a pilot study.
Topics: Aged; Bone Neoplasms; Cimetidine; Coumarins; Drug Therapy, Combination; Humans; Male; Middle Aged; N | 1990 |
The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Cimetidine; Cytotoxicity, Immunologic; Humans; Indomethacin; Interleukin-2; Ki | 1989 |